1. Home
  2. VSTS vs BEAM Comparison

VSTS vs BEAM Comparison

Compare VSTS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VSTS
  • BEAM
  • Stock Information
  • Founded
  • VSTS 1936
  • BEAM 2017
  • Country
  • VSTS United States
  • BEAM United States
  • Employees
  • VSTS N/A
  • BEAM N/A
  • Industry
  • VSTS
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VSTS
  • BEAM Health Care
  • Exchange
  • VSTS Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • VSTS 763.0M
  • BEAM 1.6B
  • IPO Year
  • VSTS N/A
  • BEAM 2020
  • Fundamental
  • Price
  • VSTS $6.15
  • BEAM $20.01
  • Analyst Decision
  • VSTS Hold
  • BEAM Strong Buy
  • Analyst Count
  • VSTS 4
  • BEAM 11
  • Target Price
  • VSTS $11.75
  • BEAM $48.90
  • AVG Volume (30 Days)
  • VSTS 2.9M
  • BEAM 2.0M
  • Earning Date
  • VSTS 08-06-2025
  • BEAM 08-05-2025
  • Dividend Yield
  • VSTS 1.71%
  • BEAM N/A
  • EPS Growth
  • VSTS N/A
  • BEAM N/A
  • EPS
  • VSTS N/A
  • BEAM N/A
  • Revenue
  • VSTS $2,731,558,000.00
  • BEAM $63,578,000.00
  • Revenue This Year
  • VSTS N/A
  • BEAM N/A
  • Revenue Next Year
  • VSTS $0.36
  • BEAM $8.82
  • P/E Ratio
  • VSTS N/A
  • BEAM N/A
  • Revenue Growth
  • VSTS N/A
  • BEAM N/A
  • 52 Week Low
  • VSTS $5.20
  • BEAM $13.53
  • 52 Week High
  • VSTS $17.83
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • VSTS 48.94
  • BEAM 68.31
  • Support Level
  • VSTS $5.56
  • BEAM $16.59
  • Resistance Level
  • VSTS $6.26
  • BEAM $17.38
  • Average True Range (ATR)
  • VSTS 0.26
  • BEAM 1.10
  • MACD
  • VSTS 0.07
  • BEAM 0.35
  • Stochastic Oscillator
  • VSTS 84.29
  • BEAM 89.70

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: